Sugi Predict

Sugi Predict / Targets / PDK4

PDK4

[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial · Q16654 · PDK4 on Sugi Atlas →

52,651 patent compounds predicted against PDK4, 27,442 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL331761 SCHEMBL331761 0.52 7/20
SCHEMBL291862 SCHEMBL291862 0.54 6/20
SCHEMBL6969 SCHEMBL6969 0.41 6/20
SCHEMBL291691 SCHEMBL291691 0.52 5/20
SCHEMBL443096 SCHEMBL443096 0.45 5/20
SCHEMBL13664 SCHEMBL13664 0.35 5/20
SCHEMBL451495 SCHEMBL451495 0.55 4/20
SCHEMBL380901 SCHEMBL380901 0.53 4/20
SCHEMBL202154 SCHEMBL202154 0.46 4/20
Norelgestromin Norelgestromin (SCHEMBL118611) 0.73 3/20
Norgestimate Norgestimate (SCHEMBL38317) 0.55 3/20
Norgestimate Norgestimate (SCHEMBL38318) 0.55 3/20
SCHEMBL420428 SCHEMBL420428 0.51 3/20
SCHEMBL149505 SCHEMBL149505 0.48 3/20
SCHEMBL420418 SCHEMBL420418 0.44 3/20
SCHEMBL383919 SCHEMBL383919 0.43 3/20
SCHEMBL219552 SCHEMBL219552 0.41 3/20
Abietic Acid Abietic Acid (SCHEMBL28888) 1.00 2/20
Abietic Acid Abietic Acid (SCHEMBL28889) 1.00 2/20
SCHEMBL319934 SCHEMBL319934 1.00 2/20

Clinical trials — most relevant to PDK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy PHASE4NOT_YET_RECRUITING
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus PHASE3COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI) PHASE2RECRUITING
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors PHASE2ACTIVE_NOT_RECRUITING
Bempedoic Acid Therapy for Polycystic Kidney Disease PHASE2NOT_YET_RECRUITING
Thiamine as an Adjunctive Therapy in Cardiac Surgery PHASE2COMPLETED
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma PHASE2UNKNOWN
Use of Phenylbutyrate Therapy for Patients With Pyruvate Dehydrogenase Complex Deficiency. PHASE2COMPLETED
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy PHASE2COMPLETED
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension PHASE1COMPLETED
Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate EARLY_PHASE1ENROLLING_BY_INVITATION
UTSW HP [13-C] Pyruvate Injection in HCM nanCOMPLETED
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis nanCOMPLETED
Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People nanCOMPLETED
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies nanRECRUITING
Acute Effect of Fructose on Lipid Metabolism and Gender Differences nanCOMPLETED
Alternative Substrates in the Critically Ill Subject nanCOMPLETED
Natural History Study of Pyruvate Dehydrogenase Deficiency nanUNKNOWN
McArdle Disease Treatment by Ketogenic Diet nanCOMPLETED
13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment nanUNKNOWN
Effect of Acute Fructose Load in Human nanCOMPLETED
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors nanRECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH) nanCOMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDK4 binder may also engage these)

ProteinNameSimilarity
PDK3 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial 1.000 landscape →
Q9JK42 — 1.000 Q9JK42 →
Q1KMR4 — 1.000 Q1KMR4 →
O70571 — 1.000 O70571 →
Q64536 — 1.000 Q64536 →
P91622 — 0.998 P91622 →
O88345 — 0.997 O88345 →
Q2KJG8 — 0.996 Q2KJG8 →
O54937 — 0.996 O54937 →
Q9P6P9 — 0.996 Q9P6P9 →
Q02332 — 0.994 Q02332 →
O02623 — 0.993 O02623 →
PDK2 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial 0.993 landscape →
O55028 — 0.992 O55028 →
P40530 — 0.992 P40530 →
Q63065 — 0.992 Q63065 →
PDK1 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial 0.992 landscape →
BCKDK Branched-chain alpha-ketoacid dehydrogenase kinase 0.991 landscape →
Q922H2 — 0.991 Q922H2 →
Q00972 — 0.991 Q00972 →
Q8BFP9 — 0.991 Q8BFP9 →
Q09116 — 0.988 Q09116 →
B6JWC1 — 0.988 B6JWC1 →
P27515 — 0.988 P27515 →
SEPTIN6 Septin-6 0.987 landscape →
P56523 — 0.987 P56523 →
Q9R1T4 — 0.987 Q9R1T4 →
A5D7Q3 — 0.987 A5D7Q3 →
Q08DA5 — 0.987 Q08DA5 →
O44476 — 0.987 O44476 →